title: Renal transplantation in systemic lupus erythematosus: a single-center experience with sixty-four cases.
abstract: The outcome of renal transplantation in 64 patients with end-stage renal disease (ESRD) secondary to lupus nephritis is the subject of this report. The patients were transplanted over a 150-month (12.5-year) period (between July 5, 1979, and January 30, 1992). The study population is predominantly made up of young females (mean age, 34.7 +/- 9 years, n = 54, 81.3%). Fifty-one transplants (79.7%) are cadaveric, and 13 (20.3%) are from living-related donors. Fifty-eight patients (90.6%) had primary (first) allografts, and 6 (9.4%) received a second allograft. Posttransplantation immunosuppression consisted of azathioprine and prednisone (AZA group, n = 22, 34.3%) or AZA, prednisone and cyclosporine (CsA group, n = 42, 65.6%). For all 64 patients combined, the 1-year graft and patient survival rates are 68.8 and 86.5%, respectively, whereas 5-year graft and patient survival rates are 60.9 and 85.9%, respectively. Patients whose immunosuppressive regimen was CsA-based had a 1-year graft survival of 71.5 versus 63.6% in the AZA group. However, this 7.9% difference did not reach statistical significance (p = 0.95). The 5-year graft survival of the CsA-based group was 69.1 versus 45.5% for the AZA group, p < 0.05. One-year patient survival was 77.3% for the AZA group and 92.9% for the CsA group, p < 0.05). The data show that patients with ESRD secondary to lupus nephritis can undergo renal transplantation with satisfactory outcome. Immunosuppression based upon CsA improves first-year patient and allograft survival by 15.6 and 7.9%. respectively.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Division of Nephrology, University of Southern California School of Medicine, Los Angeles 90033, USA.
authors.forename: M A
authors.initials: MA
authors.lastname: el-Shahawy
authors.forename: S
authors.initials: S
authors.lastname: Aswad
authors.forename: R G
authors.initials: RG
authors.lastname: Mendez
authors.forename: R
authors.initials: R
authors.lastname: Bangsil
authors.forename: R
authors.initials: R
authors.lastname: Mendez
authors.forename: S G
authors.initials: SG
authors.lastname: Massry
mesh_terms: D000328:Adult; D001379:Azathioprine / Q000627:therapeutic use; D002102:Cadaver; D016572:Cyclosporine / Q000627:therapeutic use; D005260:Female; D006085:Graft Survival; D006801:Humans; D007165:Immunosuppression Therapy; D007676:Kidney Failure, Chronic / Q000209:etiology / Q000401:mortality / Q000601:surgery*; D016030:Kidney Transplantation / Q000401:mortality; D008181:Lupus Nephritis / Q000401:mortality / Q000601:surgery*; D008297:Male; D011241:Prednisone / Q000627:therapeutic use; D015996:Survival Rate; D013997:Time Factors; D014019:Tissue Donors; D016896:Treatment Outcome
chemical_list: D016572:Cyclosporine; D001379:Azathioprine; D011241:Prednisone